Glycated hemoglobin, also known as hemoglobin A1c (HbA1c), serves as an essential biochemical marker in the diabetes management, allowing for long-term glycemic control monitoring and the identification of potential complications. Studies such as the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) have demonstrated the direct correlation between glycemic control, as measured by HbA1c, and the risk of complications. It is for this reason that diabetes organizations worldwide recommend specific HbA1c targets based on DCCT/UKPDS HbA1c. To ensure consistency in clinical laboratory results, the National Glycohemoglobin Standardization Program (NGSP) was established to standardize GHB/HbA1c results according to the DCCT standard. The BioHermes Smart HbA1c Device A1C EZ 2.0 is a handheld hemoglobin A1c device for diabetes management that utilizes boronate affinity chromatography, a patented technology in the USA, Canada, France, Ger…